 Mary Jo Fidler
Concepts (264)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 23 | 2021 | 374 | 4.350 |
Why?
| | Lung Neoplasms | 25 | 2022 | 756 | 3.900 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 11 | 2021 | 405 | 1.730 |
Why?
| | Antineoplastic Agents | 6 | 2022 | 274 | 1.280 |
Why?
| | Carcinoma, Squamous Cell | 9 | 2019 | 207 | 1.040 |
Why?
| | Quinazolines | 3 | 2012 | 27 | 1.030 |
Why?
| | Chemoradiotherapy | 9 | 2016 | 69 | 1.000 |
Why?
| | Esophagectomy | 1 | 2019 | 25 | 0.800 |
Why?
| | Sarcopenia | 1 | 2019 | 34 | 0.770 |
Why?
| | Neoplasm Staging | 17 | 2021 | 481 | 0.760 |
Why?
| | Esophageal Neoplasms | 1 | 2019 | 61 | 0.760 |
Why?
| | Kidney Glomerulus | 5 | 2019 | 96 | 0.730 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2018 | 76 | 0.710 |
Why?
| | Inflammation Mediators | 1 | 2018 | 94 | 0.680 |
Why?
| | Radiotherapy, Conformal | 2 | 2014 | 24 | 0.680 |
Why?
| | Aged | 35 | 2019 | 10295 | 0.680 |
Why?
| | Amyloidosis | 5 | 2018 | 29 | 0.670 |
Why?
| | Oropharyngeal Neoplasms | 4 | 2019 | 23 | 0.660 |
Why?
| | Pneumonectomy | 2 | 2015 | 90 | 0.650 |
Why?
| | Prognosis | 15 | 2022 | 1028 | 0.650 |
Why?
| | Neoadjuvant Therapy | 4 | 2016 | 71 | 0.640 |
Why?
| | Muscle, Skeletal | 1 | 2019 | 385 | 0.610 |
Why?
| | ErbB Receptors | 5 | 2018 | 78 | 0.590 |
Why?
| | Gene Dosage | 2 | 2012 | 27 | 0.590 |
Why?
| | PTEN Phosphohydrolase | 2 | 2011 | 12 | 0.580 |
Why?
| | Female | 40 | 2022 | 18253 | 0.560 |
Why?
| | Middle Aged | 33 | 2021 | 11209 | 0.560 |
Why?
| | Male | 39 | 2021 | 17583 | 0.560 |
Why?
| | Humans | 50 | 2022 | 31481 | 0.550 |
Why?
| | Social Class | 1 | 2014 | 71 | 0.530 |
Why?
| | Kidney Diseases | 5 | 2014 | 146 | 0.520 |
Why?
| | Kidney | 5 | 2019 | 210 | 0.520 |
Why?
| | Glomerulonephritis | 3 | 2019 | 27 | 0.500 |
Why?
| | Treatment Outcome | 23 | 2021 | 3910 | 0.500 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2019 | 136 | 0.490 |
Why?
| | Receptor, IGF Type 1 | 1 | 2012 | 21 | 0.480 |
Why?
| | Postoperative Complications | 2 | 2019 | 1083 | 0.470 |
Why?
| | Survival Analysis | 9 | 2021 | 379 | 0.460 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2011 | 50 | 0.460 |
Why?
| | Immunotherapy | 2 | 2021 | 74 | 0.430 |
Why?
| | Cyclooxygenase 2 | 2 | 2014 | 33 | 0.400 |
Why?
| | Retrospective Studies | 19 | 2022 | 3591 | 0.400 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2021 | 236 | 0.380 |
Why?
| | Survival Rate | 8 | 2018 | 465 | 0.370 |
Why?
| | Glomerulonephritis, Membranous | 2 | 2021 | 8 | 0.360 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2008 | 29 | 0.360 |
Why?
| | Glomerulonephritis, Membranoproliferative | 2 | 2018 | 5 | 0.340 |
Why?
| | Kidney Transplantation | 5 | 2019 | 141 | 0.340 |
Why?
| | Head and Neck Neoplasms | 2 | 2021 | 137 | 0.330 |
Why?
| | Adenocarcinoma | 3 | 2018 | 237 | 0.320 |
Why?
| | Proteomics | 3 | 2018 | 80 | 0.310 |
Why?
| | Adult | 17 | 2021 | 9779 | 0.300 |
Why?
| | Induction Chemotherapy | 2 | 2016 | 14 | 0.300 |
Why?
| | Follow-Up Studies | 8 | 2018 | 2028 | 0.280 |
Why?
| | Databases, Factual | 6 | 2019 | 391 | 0.280 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2014 | 39 | 0.270 |
Why?
| | Immunohistochemistry | 4 | 2021 | 494 | 0.270 |
Why?
| | Kaplan-Meier Estimate | 6 | 2021 | 230 | 0.270 |
Why?
| | Disease-Free Survival | 6 | 2018 | 241 | 0.260 |
Why?
| | Combined Modality Therapy | 6 | 2019 | 456 | 0.260 |
Why?
| | Molecular Targeted Therapy | 2 | 2015 | 39 | 0.260 |
Why?
| | Biopsy | 7 | 2019 | 283 | 0.260 |
Why?
| | Mutation | 3 | 2018 | 464 | 0.250 |
Why?
| | Aged, 80 and over | 11 | 2019 | 5234 | 0.250 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2021 | 23 | 0.250 |
Why?
| | Maytansine | 1 | 2022 | 3 | 0.250 |
Why?
| | Cohort Studies | 7 | 2021 | 2014 | 0.240 |
Why?
| | Immunoconjugates | 1 | 2022 | 13 | 0.240 |
Why?
| | United States | 5 | 2019 | 2539 | 0.240 |
Why?
| | Immunosuppressive Agents | 3 | 2019 | 163 | 0.240 |
Why?
| | Thoracic Neoplasms | 1 | 2022 | 10 | 0.240 |
Why?
| | Immunoglobulin Light Chains | 2 | 2011 | 9 | 0.240 |
Why?
| | N-Acetylglucosaminyltransferases | 1 | 2021 | 3 | 0.220 |
Why?
| | Weight Gain | 2 | 2012 | 70 | 0.220 |
Why?
| | Carcinoma, Large Cell | 2 | 2018 | 18 | 0.220 |
Why?
| | Lupus Nephritis | 1 | 2021 | 35 | 0.210 |
Why?
| | Chemoradiotherapy, Adjuvant | 3 | 2015 | 21 | 0.210 |
Why?
| | Allografts | 2 | 2019 | 171 | 0.210 |
Why?
| | Autoantibodies | 1 | 2021 | 119 | 0.210 |
Why?
| | Protein Kinase Inhibitors | 2 | 2018 | 67 | 0.200 |
Why?
| | Human papillomavirus 16 | 1 | 2019 | 8 | 0.200 |
Why?
| | Age Factors | 4 | 2018 | 943 | 0.200 |
Why?
| | Papillomavirus Infections | 2 | 2016 | 38 | 0.190 |
Why?
| | Taxoids | 2 | 2015 | 16 | 0.190 |
Why?
| | Nephrotic Syndrome | 1 | 2019 | 38 | 0.190 |
Why?
| | Biopsy, Fine-Needle | 1 | 2019 | 54 | 0.190 |
Why?
| | Neoplasms | 1 | 2022 | 280 | 0.190 |
Why?
| | Congo Red | 1 | 2018 | 2 | 0.190 |
Why?
| | Tongue Neoplasms | 1 | 2018 | 17 | 0.190 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2018 | 13 | 0.190 |
Why?
| | Antibodies, Monoclonal | 2 | 2018 | 301 | 0.190 |
Why?
| | Registries | 2 | 2022 | 214 | 0.170 |
Why?
| | Immunoglobulin G | 1 | 2018 | 134 | 0.170 |
Why?
| | Laser Capture Microdissection | 2 | 2019 | 3 | 0.170 |
Why?
| | Breast Neoplasms | 1 | 2022 | 442 | 0.170 |
Why?
| | Palliative Care | 2 | 2015 | 146 | 0.160 |
Why?
| | Quality of Life | 2 | 2019 | 663 | 0.150 |
Why?
| | Immunoglobulins | 1 | 2015 | 35 | 0.150 |
Why?
| | Robotic Surgical Procedures | 1 | 2015 | 22 | 0.150 |
Why?
| | Prostaglandins | 1 | 2014 | 4 | 0.150 |
Why?
| | Multiple Myeloma | 2 | 2012 | 37 | 0.150 |
Why?
| | Nephritis, Interstitial | 1 | 2014 | 6 | 0.140 |
Why?
| | Actuarial Analysis | 1 | 2014 | 12 | 0.140 |
Why?
| | Academies and Institutes | 1 | 2014 | 12 | 0.140 |
Why?
| | Cancer Care Facilities | 1 | 2014 | 6 | 0.140 |
Why?
| | Propensity Score | 1 | 2014 | 54 | 0.140 |
Why?
| | Parotid Gland | 1 | 2014 | 17 | 0.140 |
Why?
| | Preoperative Care | 1 | 2015 | 146 | 0.140 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2015 | 136 | 0.140 |
Why?
| | Predictive Value of Tests | 3 | 2015 | 637 | 0.130 |
Why?
| | Lymphatic Metastasis | 1 | 2014 | 107 | 0.130 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2014 | 59 | 0.130 |
Why?
| | Health Services Accessibility | 1 | 2014 | 113 | 0.130 |
Why?
| | Sulfonamides | 2 | 2014 | 64 | 0.120 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2012 | 2 | 0.120 |
Why?
| | Logistic Models | 1 | 2014 | 479 | 0.120 |
Why?
| | Tandem Mass Spectrometry | 1 | 2012 | 22 | 0.120 |
Why?
| | Prospective Studies | 1 | 2018 | 1934 | 0.120 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2011 | 6 | 0.120 |
Why?
| | Lymphoma | 1 | 2012 | 56 | 0.120 |
Why?
| | Papillomaviridae | 3 | 2016 | 30 | 0.120 |
Why?
| | Paraproteinemias | 1 | 2011 | 5 | 0.120 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2011 | 11 | 0.120 |
Why?
| | Prevalence | 1 | 2014 | 544 | 0.120 |
Why?
| | Fluorescent Antibody Technique | 3 | 2019 | 84 | 0.120 |
Why?
| | Proteins | 1 | 2012 | 94 | 0.120 |
Why?
| | Myeloproliferative Disorders | 1 | 2011 | 6 | 0.110 |
Why?
| | Young Adult | 5 | 2018 | 2277 | 0.110 |
Why?
| | Patient Selection | 3 | 2021 | 264 | 0.110 |
Why?
| | Vascular Diseases | 1 | 2011 | 59 | 0.110 |
Why?
| | Xanthine Dehydrogenase | 1 | 2010 | 7 | 0.110 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2010 | 22 | 0.100 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2010 | 28 | 0.100 |
Why?
| | Time Factors | 4 | 2019 | 1902 | 0.100 |
Why?
| | Tumor Suppressor Proteins | 1 | 2010 | 42 | 0.100 |
Why?
| | Risk Factors | 4 | 2019 | 2664 | 0.100 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2009 | 30 | 0.100 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2009 | 29 | 0.100 |
Why?
| | Glomerular Filtration Rate | 3 | 2015 | 77 | 0.100 |
Why?
| | Radiotherapy | 1 | 2009 | 65 | 0.100 |
Why?
| | Signal Transduction | 1 | 2012 | 588 | 0.090 |
Why?
| | Disease Progression | 3 | 2021 | 861 | 0.090 |
Why?
| | Peptic Ulcer | 1 | 2008 | 8 | 0.090 |
Why?
| | In Situ Hybridization | 1 | 2008 | 63 | 0.090 |
Why?
| | DNA Methylation | 1 | 2010 | 168 | 0.090 |
Why?
| | Antibodies, Antineutrophil Cytoplasmic | 2 | 2019 | 10 | 0.090 |
Why?
| | Pyrazoles | 1 | 2008 | 55 | 0.080 |
Why?
| | Risk Assessment | 3 | 2019 | 806 | 0.080 |
Why?
| | Mass Spectrometry | 2 | 2019 | 43 | 0.080 |
Why?
| | Blood Group Incompatibility | 1 | 2005 | 2 | 0.080 |
Why?
| | Splenectomy | 1 | 2005 | 8 | 0.080 |
Why?
| | ABO Blood-Group System | 1 | 2005 | 7 | 0.080 |
Why?
| | Sensitivity and Specificity | 2 | 2019 | 580 | 0.080 |
Why?
| | Kidney Failure, Chronic | 2 | 2021 | 176 | 0.080 |
Why?
| | Graft Rejection | 1 | 2005 | 84 | 0.070 |
Why?
| | Lymph Nodes | 2 | 2016 | 84 | 0.070 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2018 | 25 | 0.070 |
Why?
| | Creatinine | 2 | 2015 | 59 | 0.070 |
Why?
| | Case-Control Studies | 3 | 2012 | 687 | 0.070 |
Why?
| | Drug Administration Schedule | 2 | 2015 | 257 | 0.070 |
Why?
| | Adolescent | 3 | 2018 | 2667 | 0.070 |
Why?
| | Radiotherapy Dosage | 2 | 2015 | 149 | 0.070 |
Why?
| | Recurrence | 2 | 2018 | 389 | 0.070 |
Why?
| | Etoposide | 2 | 2015 | 64 | 0.070 |
Why?
| | Carboplatin | 2 | 2015 | 52 | 0.070 |
Why?
| | Microscopy, Electron | 2 | 2015 | 100 | 0.070 |
Why?
| | Paclitaxel | 2 | 2015 | 80 | 0.070 |
Why?
| | Tumor Microenvironment | 1 | 2022 | 16 | 0.060 |
Why?
| | Minnesota | 2 | 2012 | 12 | 0.060 |
Why?
| | Analysis of Variance | 2 | 2015 | 364 | 0.060 |
Why?
| | Kidney Function Tests | 2 | 2012 | 29 | 0.060 |
Why?
| | Phototherapy | 1 | 2021 | 39 | 0.060 |
Why?
| | Proportional Hazards Models | 2 | 2014 | 390 | 0.060 |
Why?
| | C-Reactive Protein | 1 | 2022 | 134 | 0.060 |
Why?
| | Antigens, Neoplasm | 1 | 2021 | 53 | 0.050 |
Why?
| | Proteinuria | 2 | 2012 | 116 | 0.050 |
Why?
| | Observer Variation | 1 | 2021 | 146 | 0.050 |
Why?
| | Genetic Heterogeneity | 1 | 2019 | 8 | 0.050 |
Why?
| | Phenotype | 1 | 2021 | 379 | 0.050 |
Why?
| | Reference Values | 1 | 2019 | 260 | 0.050 |
Why?
| | Neoplasm Invasiveness | 1 | 2018 | 104 | 0.050 |
Why?
| | Graft Survival | 1 | 2018 | 111 | 0.040 |
Why?
| | Radiation Pneumonitis | 1 | 2015 | 4 | 0.040 |
Why?
| | Hemoptysis | 1 | 2015 | 9 | 0.040 |
Why?
| | Esophagitis | 1 | 2015 | 11 | 0.040 |
Why?
| | Cough | 1 | 2015 | 12 | 0.040 |
Why?
| | Markov Chains | 1 | 2015 | 32 | 0.040 |
Why?
| | Quality-Adjusted Life Years | 1 | 2015 | 25 | 0.040 |
Why?
| | Chest Pain | 1 | 2015 | 23 | 0.040 |
Why?
| | Paraffin Embedding | 1 | 2015 | 5 | 0.040 |
Why?
| | Complement C3 | 1 | 2015 | 10 | 0.040 |
Why?
| | Tissue Fixation | 1 | 2015 | 11 | 0.040 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2015 | 84 | 0.040 |
Why?
| | Dyspnea | 1 | 2015 | 35 | 0.040 |
Why?
| | False Positive Reactions | 1 | 2015 | 40 | 0.040 |
Why?
| | Neoplasm, Residual | 1 | 2015 | 10 | 0.040 |
Why?
| | Radiation Injuries | 1 | 2015 | 44 | 0.040 |
Why?
| | Lymph Node Excision | 1 | 2015 | 37 | 0.040 |
Why?
| | Diagnostic Errors | 1 | 2015 | 48 | 0.040 |
Why?
| | Guanine | 1 | 2014 | 11 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2015 | 153 | 0.040 |
Why?
| | Glutamates | 1 | 2014 | 19 | 0.040 |
Why?
| | Pyrroles | 1 | 2014 | 22 | 0.040 |
Why?
| | Proton Pump Inhibitors | 1 | 2014 | 15 | 0.040 |
Why?
| | Steroids | 1 | 2014 | 30 | 0.040 |
Why?
| | Glomerular Basement Membrane | 1 | 2014 | 2 | 0.040 |
Why?
| | Carcinoma | 1 | 2015 | 84 | 0.030 |
Why?
| | Antibodies | 1 | 2014 | 72 | 0.030 |
Why?
| | Mobility Limitation | 1 | 2015 | 100 | 0.030 |
Why?
| | Autoimmune Diseases | 1 | 2014 | 66 | 0.030 |
Why?
| | Acute Disease | 1 | 2014 | 254 | 0.030 |
Why?
| | Patient Readmission | 1 | 2015 | 129 | 0.030 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2014 | 78 | 0.030 |
Why?
| | Diet | 1 | 2015 | 202 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2014 | 559 | 0.030 |
Why?
| | Laser Therapy | 1 | 2012 | 17 | 0.030 |
Why?
| | Sequence Analysis, Protein | 1 | 2012 | 5 | 0.030 |
Why?
| | Length of Stay | 1 | 2015 | 377 | 0.030 |
Why?
| | Heavy Chain Disease | 1 | 2011 | 2 | 0.030 |
Why?
| | Electrophoresis | 1 | 2011 | 23 | 0.030 |
Why?
| | Sex Distribution | 1 | 2012 | 89 | 0.030 |
Why?
| | Age Distribution | 1 | 2012 | 110 | 0.030 |
Why?
| | Amino Acid Sequence | 1 | 2012 | 254 | 0.030 |
Why?
| | Polycythemia Vera | 1 | 2011 | 5 | 0.030 |
Why?
| | Thrombocythemia, Essential | 1 | 2011 | 2 | 0.030 |
Why?
| | Molecular Sequence Data | 1 | 2012 | 315 | 0.030 |
Why?
| | Biopsy, Needle | 1 | 2012 | 117 | 0.030 |
Why?
| | Primary Myelofibrosis | 1 | 2011 | 5 | 0.030 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2011 | 14 | 0.030 |
Why?
| | Child, Preschool | 1 | 2014 | 786 | 0.030 |
Why?
| | Activities of Daily Living | 1 | 2015 | 495 | 0.030 |
Why?
| | Stem Cell Transplantation | 1 | 2011 | 54 | 0.030 |
Why?
| | Transplantation, Autologous | 1 | 2011 | 223 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2014 | 412 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2012 | 158 | 0.030 |
Why?
| | Gene Amplification | 1 | 2010 | 28 | 0.030 |
Why?
| | Echocardiography | 1 | 2011 | 197 | 0.030 |
Why?
| | Monomeric GTP-Binding Proteins | 1 | 2010 | 4 | 0.030 |
Why?
| | Death-Associated Protein Kinases | 1 | 2010 | 5 | 0.030 |
Why?
| | DNA Modification Methylases | 1 | 2010 | 6 | 0.030 |
Why?
| | DNA Repair Enzymes | 1 | 2010 | 9 | 0.030 |
Why?
| | Remission Induction | 1 | 2010 | 119 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2011 | 390 | 0.030 |
Why?
| | Immunoenzyme Techniques | 1 | 2010 | 54 | 0.030 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2010 | 42 | 0.030 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2011 | 86 | 0.030 |
Why?
| | Cadherins | 1 | 2010 | 38 | 0.030 |
Why?
| | CpG Islands | 1 | 2010 | 53 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2010 | 60 | 0.030 |
Why?
| | Comorbidity | 1 | 2012 | 562 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2010 | 108 | 0.030 |
Why?
| | Antigens, CD | 1 | 2010 | 106 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2010 | 94 | 0.020 |
Why?
| | Algorithms | 1 | 2012 | 412 | 0.020 |
Why?
| | Lung | 1 | 2010 | 171 | 0.020 |
Why?
| | Child | 1 | 2014 | 1572 | 0.020 |
Why?
| | Smoking | 1 | 2010 | 202 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 891 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2010 | 378 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2012 | 1240 | 0.020 |
Why?
| | Transplantation Conditioning | 1 | 2005 | 40 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2005 | 265 | 0.020 |
Why?
| | Tissue Donors | 1 | 2005 | 79 | 0.020 |
Why?
| | Animals | 1 | 2010 | 5312 | 0.010 |
Why?
|
|
Fidler's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|